Anna French
SlowingNamed in filings at Qiming U.S HealthcareOn the current fund
- Board seats filed
- 6
- Named on a board
- 1
all filings on record
Named in filings at Qiming U.S HealthcareOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Renasant Bio | Biotech & pharma | June 2025 | Atlas Venture |
| Entact Bio | Biotech & pharma | January 2024 | None on file |
| Umoja Biopharma | Biotech & pharma | June 2021 | MPM BioVentures |
| CARDIALEN | Digital health | June 2021 | None on file |
| WindMIL Therapeutics | Biotech & pharma | January 2021 | Domain Partners |
| Auron Therapeutics | Biotech & pharma | December 2020 | Polaris Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Anna French on the board, based on 6 filed seats with a verified or cited source.